Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.73 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211020 | 0.90 | NOTUM (0.67) | PLK1NOTUMALDH1A1CHRNA7CA1 | |
| SCHEMBL5922325 | 0.90 | NOTUM (0.67) | PLK1NOTUMALDH1A1CHRNA7 | |
| SCHEMBL27535987 | 0.90 | PLK1 (0.60) | PLK1NOTUMALDH1A1CHRNA7CA1 | |
| SCHEMBL10369631 | 0.89 | PLK1 (0.71) | PLK1NOTUMALDH1A1CHRNA7CA1 | |
| SCHEMBL27542192 | 0.88 | NOTUM (0.70) | PLK1NOTUMALDH1A1CHRNA7TP53 | |
| SCHEMBL6457336 | 0.87 | PLK1 (0.69) | PLK1NOTUMALDH1A1CHRNA7CA1 | |
| SCHEMBL4265600 | 0.87 | PLK1 (0.58) | PLK1NOTUMALDH1A1CHRNA7CA1 | |
| SCHEMBL4265653 | 0.87 | PLK1 (0.58) | PLK1NOTUMALDH1A1CHRNA7TP53 | |
| SCHEMBL27535986 | 0.87 | PLK1 (0.58) | PLK1NOTUMALDH1A1CHRNA7MYC | |
| SCHEMBL27512288 | 0.87 | NOTUM (0.71) | PLK1NOTUMALDH1A1TP53PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| EP-2376454-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110224193-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| WO-2010059611-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| US-20060198893-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides | ASTRAZENECA AB (SE) | 2006-09-07 | — | — | US | disclosed |
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1592404-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE PYRROLE CARBOXAMIDE AND AN EXCIPIENT LIKE MIDDLE CHAIN TRIGLYCERIDES | AstraZeneca AB (SE) | 2005-11-09 | — | — | EP | disclosed |
| EP-1578417-A1 | 1,5-DIARYL-PYRROLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| WO-2004069227-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE PYRROLE CARBOXAMIDE AND EXCIPIENT LIKE MIDDLE CHAIN TRIGLYCERIDES | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004058249-A1 | 1,5-DIARYL-PYRROLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1432679-A1 | PREPARATION AND USE OF PYRROLE DERIVATIVES FOR TREATING OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027069-A1 | PREPARATION AND USE OF PYRROLE DERIVATIVES FOR TREATING OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224193-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | PLK1 2539/4885NOTUM 359/4885ALDH1A1 928/4885 |
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | PLK1 4848/4885NOTUM 4494/4885ALDH1A1 2159/4885 |
| US-20060198893-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides | CETP, PNLIP, LIPC | PLK1 1060/4885NOTUM 19/4885ALDH1A1 1550/4885 |
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | PGC, GIPR, GPR119 | PLK1 1601/4885NOTUM 1376/4885ALDH1A1 1881/4885 |
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | PLK1 4623/4885NOTUM 2381/4885ALDH1A1 2330/4885 |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | PLK1 328/4885NOTUM 4859/4885ALDH1A1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.